N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase
- PMID: 11431347
N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase
Abstract
The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Cancer Inst. (Bethesda), 91: 1138-1146, 1999). Here we determine whether the increased ceramide mediated by 4-HPR in the CHLA-90 human neuroblastoma cell line results from de novo ceramide synthesis. Treatment of CHLA-90 with 4-HPR for 2 h, in the presence of [(3)H]palmitic acid, caused sequential formation of [(3)H]sphinganine (220% over control) and [(3)H]ceramide (160% over control), with sphinganine returning to baseline at 4 h, and ceramide continuing to increase (215% over control). 4-HPR treatment did not accelerate cellular decay of sphingomyelin. Preincubation of cells with either L-cycloserine, an inhibitor of serine palmitoyltransferase (SPT), or fumonisin B(1), an inhibitor of ceramide synthase, retarded ceramide formation in response to 4-HPR treatment, although sphinganine was still generated when 4-HPR and FB(1) were present. Data from in vitro enzyme assays using microsomes showed that preexposure of intact cells to 4-HPR resulted in a time (175% over control; 6 h)- and dose-dependent increase (173% over control; 10 microM) in SPT activity as well as a time (265% over control)- and dose-dependent increase (215% above control; 10 microM) in ceramide synthase activity. Our results show that 4-HPR-mediated ceramide generation is derived from the de novo synthetic pathway by coordinate activation of SPT and ceramide synthase. Knowledge of these biochemical events is of utility when downstream modulators of ceramide metabolism are used to heighten the cytotoxic response to chemotherapy.
Similar articles
-
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.Cancer Res. 2004 Aug 1;64(15):5415-24. doi: 10.1158/0008-5472.CAN-04-0377. Cancer Res. 2004. PMID: 15289350
-
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.Leukemia. 2002 May;16(5):902-10. doi: 10.1038/sj.leu.2402485. Leukemia. 2002. PMID: 11986953
-
4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.Cancer Res. 2006 Mar 15;66(6):3238-47. doi: 10.1158/0008-5472.CAN-05-3362. Cancer Res. 2006. PMID: 16540676
-
Ceramide synthesis and metabolism as a _target for cancer therapy.Cancer Lett. 2004 Apr 8;206(2):169-80. doi: 10.1016/j.canlet.2003.08.034. Cancer Lett. 2004. PMID: 15013522 Review.
-
The role of gangliosides in fenretinide-induced apoptosis of neuroblastoma.Cancer Lett. 2005 Oct 18;228(1-2):105-10. doi: 10.1016/j.canlet.2005.01.044. Cancer Lett. 2005. PMID: 15907365 Review.
Cited by
-
Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.Leuk Res. 2015 Oct;39(10):1071-8. doi: 10.1016/j.leukres.2015.06.009. Epub 2015 Jul 2. Leuk Res. 2015. PMID: 26220867 Free PMC article.
-
Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.Biochem Cell Biol. 2012 Apr;90(2):209-23. doi: 10.1139/o2012-001. Epub 2012 Mar 19. Biochem Cell Biol. 2012. PMID: 22428532 Free PMC article.
-
Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases.PLoS One. 2013 Jul 31;8(7):e70002. doi: 10.1371/journal.pone.0070002. Print 2013. PLoS One. 2013. PMID: 23936132 Free PMC article.
-
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.Cancer Chemother Pharmacol. 2023 Aug;92(2):97-105. doi: 10.1007/s00280-023-04543-6. Epub 2023 May 18. Cancer Chemother Pharmacol. 2023. PMID: 37199745 Clinical Trial.
-
Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.Clin Cancer Res. 2017 Aug 15;23(16):4550-4555. doi: 10.1158/1078-0432.CCR-17-0234. Epub 2017 Apr 18. Clin Cancer Res. 2017. PMID: 28420721 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical